CHAPTER 1: INTRODUCTION
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET LANDSCAPE
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
3.3.1. Bargaining Power of Suppliers
3.3.2. Threat of New Entrants
3.3.3. Threat of Substitutes
3.3.4. Competitive Rivalry
3.3.5. Bargaining Power among Buyers
3.4. Market Dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
CHAPTER 4: EUROPE VACCINES MARKET, BY TECHNOLOGY TYPE
4.1. Market Overview
4.1.1 Market Size and Forecast, By Technology Type
4.2. Inactivated Vaccines
4.2.1. Key Market Trends, Growth Factors and Opportunities
4.2.2. Market Share Analysis, By Country
4.3. Toxoid Vaccines
4.3.1. Key Market Trends, Growth Factors and Opportunities
4.3.2. Market Share Analysis, By Country
4.4. Recombinant And Conjugate Vaccines
4.4.1. Key Market Trends, Growth Factors and Opportunities
4.4.2. Market Share Analysis, By Country
4.5. Live Attenuated Vaccines
4.5.1. Key Market Trends, Growth Factors and Opportunities
4.5.2. Market Share Analysis, By Country
4.6. Others
4.6.1. Key Market Trends, Growth Factors and Opportunities
4.6.2. Market Share Analysis, By Country
CHAPTER 5: EUROPE VACCINES MARKET, BY INDICATION
5.1. Market Overview
5.1.1 Market Size and Forecast, By Indication
5.2. Pneumococcal Disease
5.2.1. Key Market Trends, Growth Factors and Opportunities
5.2.2. Market Share Analysis, By Country
5.3. Influenza
5.3.1. Key Market Trends, Growth Factors and Opportunities
5.3.2. Market Share Analysis, By Country
5.4. Human Papilloma Virus
5.4.1. Key Market Trends, Growth Factors and Opportunities
5.4.2. Market Share Analysis, By Country
5.5. Meningococcal Disease
5.5.1. Key Market Trends, Growth Factors and Opportunities
5.5.2. Market Share Analysis, By Country
5.6. Rotavirus
5.6.1. Key Market Trends, Growth Factors and Opportunities
5.6.2. Market Share Analysis, By Country
5.7. Varicella
5.7.1. Key Market Trends, Growth Factors and Opportunities
5.7.2. Market Share Analysis, By Country
5.8. Measles, Mumps, And Rubella
5.8.1. Key Market Trends, Growth Factors and Opportunities
5.8.2. Market Share Analysis, By Country
5.9. Diphtheria, Pertussis, And Tetanus (DTP)
5.9.1. Key Market Trends, Growth Factors and Opportunities
5.9.2. Market Share Analysis, By Country
5.10. Polio
5.10.1. Key Market Trends, Growth Factors and Opportunities
5.10.2. Market Share Analysis, By Country
5.11. Hepatitis
5.11.1. Key Market Trends, Growth Factors and Opportunities
5.11.2. Market Share Analysis, By Country
5.12. Other Indications
5.12.1. Key Market Trends, Growth Factors and Opportunities
5.12.2. Market Share Analysis, By Country
CHAPTER 6: EUROPE VACCINES MARKET, BY END USER
6.1. Market Overview
6.1.1 Market Size and Forecast, By End User
6.2. Pediatric
6.2.1. Key Market Trends, Growth Factors and Opportunities
6.2.2. Market Share Analysis, By Country
6.3. Adults
6.3.1. Key Market Trends, Growth Factors and Opportunities
6.3.2. Market Share Analysis, By Country
6.4. Travelers
6.4.1. Key Market Trends, Growth Factors and Opportunities
6.4.2. Market Share Analysis, By Country
CHAPTER 7: EUROPE VACCINES MARKET, BY COUNTRY
7.1. Market Overview
7.1.1 Market Size and Forecast, By Country
7.2. Europe
7.2.2. Key Market Trends and Opportunities
7.2.2. Market Size and Forecast, By Technology Type
7.2.3. Market Size and Forecast, By Indication
7.2.4. Market Size and Forecast, By End User
7.2.5. Market Size and Forecast, By Country
7.2.6.Germany
7.2.6.1. Market Size and Forecast, By Technology Type
7.2.6.2. Market Size and Forecast, By Indication
7.2.6.3. Market Size and Forecast, By End User
7.2.7.France
7.2.7.1. Market Size and Forecast, By Technology Type
7.2.7.2. Market Size and Forecast, By Indication
7.2.7.3. Market Size and Forecast, By End User
7.2.8.UK
7.2.8.1. Market Size and Forecast, By Technology Type
7.2.8.2. Market Size and Forecast, By Indication
7.2.8.3. Market Size and Forecast, By End User
7.2.9.Italy
7.2.9.1. Market Size and Forecast, By Technology Type
7.2.9.2. Market Size and Forecast, By Indication
7.2.9.3. Market Size and Forecast, By End User
7.2.10.Spain
7.2.10.1. Market Size and Forecast, By Technology Type
7.2.10.2. Market Size and Forecast, By Indication
7.2.10.3. Market Size and Forecast, By End User
7.2.11.Rest Of Europe
7.2.11.1. Market Size and Forecast, By Technology Type
7.2.11.2. Market Size and Forecast, By Indication
7.2.11.3. Market Size and Forecast, By End User
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top Winning Strategies
8.3. Product Mapping Of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top Player Positioning,2023
CHAPTER 9: COMPANY PROFILES
9.1. Pfizer
9.1.1. Company Overview
9.1.2. Key Executives
9.1.3. Company Snapshot
9.1.4. Operating Business Segments
9.1.5. Product Portfolio
9.1.6. Business Performance
9.1.7. Key Strategic Moves and Developments
9.2. Bavarian Nordic A/S
9.2.1. Company Overview
9.2.2. Key Executives
9.2.3. Company Snapshot
9.2.4. Operating Business Segments
9.2.5. Product Portfolio
9.2.6. Business Performance
9.2.7. Key Strategic Moves and Developments
9.3. Valneva SE
9.3.1. Company Overview
9.3.2. Key Executives
9.3.3. Company Snapshot
9.3.4. Operating Business Segments
9.3.5. Product Portfolio
9.3.6. Business Performance
9.3.7. Key Strategic Moves and Developments
9.4. Viatris Inc.
9.4.1. Company Overview
9.4.2. Key Executives
9.4.3. Company Snapshot
9.4.4. Operating Business Segments
9.4.5. Product Portfolio
9.4.6. Business Performance
9.4.7. Key Strategic Moves and Developments
9.5. AstraZeneca
9.5.1. Company Overview
9.5.2. Key Executives
9.5.3. Company Snapshot
9.5.4. Operating Business Segments
9.5.5. Product Portfolio
9.5.6. Business Performance
9.5.7. Key Strategic Moves and Developments
9.6. Emergex Vaccines
9.6.1. Company Overview
9.6.2. Key Executives
9.6.3. Company Snapshot
9.6.4. Operating Business Segments
9.6.5. Product Portfolio
9.6.6. Business Performance
9.6.7. Key Strategic Moves and Developments
9.7. Sanofi
9.7.1. Company Overview
9.7.2. Key Executives
9.7.3. Company Snapshot
9.7.4. Operating Business Segments
9.7.5. Product Portfolio
9.7.6. Business Performance
9.7.7. Key Strategic Moves and Developments
9.8. Prokarium
9.8.1. Company Overview
9.8.2. Key Executives
9.8.3. Company Snapshot
9.8.4. Operating Business Segments
9.8.5. Product Portfolio
9.8.6. Business Performance
9.8.7. Key Strategic Moves and Developments
9.9. Merck And Co., Inc.
9.9.1. Company Overview
9.9.2. Key Executives
9.9.3. Company Snapshot
9.9.4. Operating Business Segments
9.9.5. Product Portfolio
9.9.6. Business Performance
9.9.7. Key Strategic Moves and Developments
9.10. GSK Plc.
9.10.1. Company Overview
9.10.2. Key Executives
9.10.3. Company Snapshot
9.10.4. Operating Business Segments
9.10.5. Product Portfolio
9.10.6. Business Performance
9.10.7. Key Strategic Moves and Developments
LIST OF TABLES
TABLE 1. EUROPE VACCINES MARKET, BY TECHNOLOGY TYPE, 2024 - 2033 ($BILLION)
TABLE 2. EUROPE VACCINES MARKET FOR INACTIVATED VACCINES, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 3. EUROPE VACCINES MARKET FOR TOXOID VACCINES, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 4. EUROPE VACCINES MARKET FOR RECOMBINANT AND CONJUGATE VACCINES, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 5. EUROPE VACCINES MARKET FOR LIVE ATTENUATED VACCINES, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 6. EUROPE VACCINES MARKET FOR OTHERS, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 7. EUROPE VACCINES MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 8. EUROPE VACCINES MARKET FOR PNEUMOCOCCAL DISEASE, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 9. EUROPE VACCINES MARKET FOR INFLUENZA, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 10. EUROPE VACCINES MARKET FOR HUMAN PAPILLOMA VIRUS, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 11. EUROPE VACCINES MARKET FOR MENINGOCOCCAL DISEASE, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 12. EUROPE VACCINES MARKET FOR ROTAVIRUS, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 13. EUROPE VACCINES MARKET FOR VARICELLA, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 14. EUROPE VACCINES MARKET FOR MEASLES, MUMPS, AND RUBELLA, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 15. EUROPE VACCINES MARKET FOR DIPHTHERIA, PERTUSSIS, AND TETANUS (DTP), BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 16. EUROPE VACCINES MARKET FOR POLIO, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 17. EUROPE VACCINES MARKET FOR HEPATITIS, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 18. EUROPE VACCINES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 19. EUROPE VACCINES MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 20. EUROPE VACCINES MARKET FOR PEDIATRIC, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 21. EUROPE VACCINES MARKET FOR ADULTS, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 22. EUROPE VACCINES MARKET FOR TRAVELERS, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 23. EUROPE VACCINES MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 24. EUROPE VACCINES MARKET, BY TECHNOLOGY TYPE, 2024 - 2033 ($BILLION)
TABLE 25. EUROPE VACCINES MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 26. EUROPE VACCINES MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 27. GERMANY VACCINES MARKET, BY TECHNOLOGY TYPE, 2024 - 2033 ($BILLION)
TABLE 28. GERMANY VACCINES MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 29. GERMANY VACCINES MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 30. FRANCE VACCINES MARKET, BY TECHNOLOGY TYPE, 2024 - 2033 ($BILLION)
TABLE 31. FRANCE VACCINES MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 32. FRANCE VACCINES MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 33. UK VACCINES MARKET, BY TECHNOLOGY TYPE, 2024 - 2033 ($BILLION)
TABLE 34. UK VACCINES MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 35. UK VACCINES MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 36. ITALY VACCINES MARKET, BY TECHNOLOGY TYPE, 2024 - 2033 ($BILLION)
TABLE 37. ITALY VACCINES MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 38. ITALY VACCINES MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 39. SPAIN VACCINES MARKET, BY TECHNOLOGY TYPE, 2024 - 2033 ($BILLION)
TABLE 40. SPAIN VACCINES MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 41. SPAIN VACCINES MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 42. REST OF EUROPE VACCINES MARKET, BY TECHNOLOGY TYPE, 2024 - 2033 ($BILLION)
TABLE 43. REST OF EUROPE VACCINES MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 44. REST OF EUROPE VACCINES MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 45. PFIZER: KEY EXECUTIVES
TABLE 46. PFIZER: COMPANY SNAPSHOT
TABLE 47. PFIZER: OPERATING SEGMENTS
TABLE 48. PFIZER: PRODUCT PORTFOLIO
TABLE 49. PFIZER: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 50. BAVARIAN NORDIC A/S: KEY EXECUTIVES
TABLE 51. BAVARIAN NORDIC A/S: COMPANY SNAPSHOT
TABLE 52. BAVARIAN NORDIC A/S: OPERATING SEGMENTS
TABLE 53. BAVARIAN NORDIC A/S: PRODUCT PORTFOLIO
TABLE 54. BAVARIAN NORDIC A/S: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 55. VALNEVA SE: KEY EXECUTIVES
TABLE 56. VALNEVA SE: COMPANY SNAPSHOT
TABLE 57. VALNEVA SE: OPERATING SEGMENTS
TABLE 58. VALNEVA SE: PRODUCT PORTFOLIO
TABLE 59. VALNEVA SE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 60. VIATRIS INC.: KEY EXECUTIVES
TABLE 61. VIATRIS INC.: COMPANY SNAPSHOT
TABLE 62. VIATRIS INC.: OPERATING SEGMENTS
TABLE 63. VIATRIS INC.: PRODUCT PORTFOLIO
TABLE 64. VIATRIS INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 65. ASTRAZENECA: KEY EXECUTIVES
TABLE 66. ASTRAZENECA: COMPANY SNAPSHOT
TABLE 67. ASTRAZENECA: OPERATING SEGMENTS
TABLE 68. ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 69. ASTRAZENECA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 70. EMERGEX VACCINES: KEY EXECUTIVES
TABLE 71. EMERGEX VACCINES: COMPANY SNAPSHOT
TABLE 72. EMERGEX VACCINES: OPERATING SEGMENTS
TABLE 73. EMERGEX VACCINES: PRODUCT PORTFOLIO
TABLE 74. EMERGEX VACCINES: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 75. SANOFI: KEY EXECUTIVES
TABLE 76. SANOFI: COMPANY SNAPSHOT
TABLE 77. SANOFI: OPERATING SEGMENTS
TABLE 78. SANOFI: PRODUCT PORTFOLIO
TABLE 79. SANOFI: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 80. PROKARIUM: KEY EXECUTIVES
TABLE 81. PROKARIUM: COMPANY SNAPSHOT
TABLE 82. PROKARIUM: OPERATING SEGMENTS
TABLE 83. PROKARIUM: PRODUCT PORTFOLIO
TABLE 84. PROKARIUM: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 85. MERCK AND CO., INC.: KEY EXECUTIVES
TABLE 86. MERCK AND CO., INC.: COMPANY SNAPSHOT
TABLE 87. MERCK AND CO., INC.: OPERATING SEGMENTS
TABLE 88. MERCK AND CO., INC.: PRODUCT PORTFOLIO
TABLE 89. MERCK AND CO., INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 90. GSK PLC.: KEY EXECUTIVES
TABLE 91. GSK PLC.: COMPANY SNAPSHOT
TABLE 92. GSK PLC.: OPERATING SEGMENTS
TABLE 93. GSK PLC.: PRODUCT PORTFOLIO
TABLE 94. GSK PLC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
LIST OF FIGURES
FIGURE 1. EUROPE VACCINES MARKET,2024 - 2033
FIGURE 2. SEGMENTATION OF EUROPE VACCINES MARKET,2024 - 2033
FIGURE 3. TOP INVESTMENT POCKET IN EUROPE VACCINES MARKET,2024 - 2033
FIGURE 4. MODERATE BARGAINING POWER OF BUYERS
FIGURE 5. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 6. MODERATE THREAT OF NEW ENTRANTS
FIGURE 7. LOW THREAT OF SUBSTITUTION
FIGURE 8. HIGH COMPETITIVE RIVALRY
FIGURE 9. OPPORTUNITIES, RESTRAINTS AND DRIVERS: EUROPE VACCINES MARKET
FIGURE 10. EUROPE VACCINES MARKET , BY TECHNOLOGY TYPE,2024 - 2033 ($BILLION)
FIGURE 11. EUROPE VACCINES MARKET FOR INACTIVATED VACCINES, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 12. EUROPE VACCINES MARKET FOR TOXOID VACCINES, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 13. EUROPE VACCINES MARKET FOR RECOMBINANT AND CONJUGATE VACCINES, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 14. EUROPE VACCINES MARKET FOR LIVE ATTENUATED VACCINES, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 15. EUROPE VACCINES MARKET FOR OTHERS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 16. EUROPE VACCINES MARKET , BY INDICATION,2024 - 2033 ($BILLION)
FIGURE 17. EUROPE VACCINES MARKET FOR PNEUMOCOCCAL DISEASE, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 18. EUROPE VACCINES MARKET FOR INFLUENZA, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 19. EUROPE VACCINES MARKET FOR HUMAN PAPILLOMA VIRUS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 20. EUROPE VACCINES MARKET FOR MENINGOCOCCAL DISEASE, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 21. EUROPE VACCINES MARKET FOR ROTAVIRUS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 22. EUROPE VACCINES MARKET FOR VARICELLA, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 23. EUROPE VACCINES MARKET FOR MEASLES, MUMPS, AND RUBELLA, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 24. EUROPE VACCINES MARKET FOR DIPHTHERIA, PERTUSSIS, AND TETANUS (DTP), BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 25. EUROPE VACCINES MARKET FOR POLIO, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 26. EUROPE VACCINES MARKET FOR HEPATITIS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 27. EUROPE VACCINES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 28. EUROPE VACCINES MARKET , BY END USER,2024 - 2033 ($BILLION)
FIGURE 29. EUROPE VACCINES MARKET FOR PEDIATRIC, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 30. EUROPE VACCINES MARKET FOR ADULTS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 31. EUROPE VACCINES MARKET FOR TRAVELERS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 32. TOP WINNING STRATEGIES, BY YEAR, 2021-2023*
FIGURE 33. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2021-2023*
FIGURE 34. TOP WINNING STRATEGIES, BY COMPANY, 2021-2023*
FIGURE 35. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 36. COMPETITIVE DASHBOARD
FIGURE 37. COMPETITIVE HEATMAP: EUROPE VACCINES MARKET
FIGURE 38. TOP PLAYER POSITIONING,2023
FIGURE 39. PFIZER: NET SALES, 2021-2023 ($BILLION)
FIGURE 40. PFIZER: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 41. PFIZER: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 42. BAVARIAN NORDIC A/S: NET SALES, 2021-2023 ($BILLION)
FIGURE 43. BAVARIAN NORDIC A/S: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 44. BAVARIAN NORDIC A/S: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 45. VALNEVA SE: NET SALES, 2021-2023 ($BILLION)
FIGURE 46. VALNEVA SE: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 47. VALNEVA SE: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 48. VIATRIS INC.: NET SALES, 2021-2023 ($BILLION)
FIGURE 49. VIATRIS INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 50. VIATRIS INC.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 51. ASTRAZENECA: NET SALES, 2021-2023 ($BILLION)
FIGURE 52. ASTRAZENECA: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 53. ASTRAZENECA: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 54. EMERGEX VACCINES: NET SALES, 2021-2023 ($BILLION)
FIGURE 55. EMERGEX VACCINES: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 56. EMERGEX VACCINES: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 57. SANOFI: NET SALES, 2021-2023 ($BILLION)
FIGURE 58. SANOFI: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 59. SANOFI: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 60. PROKARIUM: NET SALES, 2021-2023 ($BILLION)
FIGURE 61. PROKARIUM: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 62. PROKARIUM: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 63. MERCK AND CO., INC.: NET SALES, 2021-2023 ($BILLION)
FIGURE 64. MERCK AND CO., INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 65. MERCK AND CO., INC.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 66. GSK PLC.: NET SALES, 2021-2023 ($BILLION)
FIGURE 67. GSK PLC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 68. GSK PLC.: REVENUE SHARE, BY REGION, 2023 (%)
LIST OF TABLES
Table 1. Europe Vaccines Market, by Technology Type, 2024 - 2033 ($Billion)
Table 2. Europe Vaccines Market for Inactivated Vaccines, by Country, 2024 - 2033 ($Billion)
Table 3. Europe Vaccines Market for Toxoid Vaccines, by Country, 2024 - 2033 ($Billion)
Table 4. Europe Vaccines Market for Recombinant and Conjugate Vaccines, by Country, 2024 - 2033 ($Billion)
Table 5. Europe Vaccines Market for Live Attenuated Vaccines, by Country, 2024 - 2033 ($Billion)
Table 6. Europe Vaccines Market for Others, by Country, 2024 - 2033 ($Billion)
Table 7. Europe Vaccines Market, by Indication, 2024 - 2033 ($Billion)
Table 8. Europe Vaccines Market for Pneumococcal Disease, by Country, 2024 - 2033 ($Billion)
Table 9. Europe Vaccines Market for Influenza, by Country, 2024 - 2033 ($Billion)
Table 10. Europe Vaccines Market for Human Papilloma Virus, by Country, 2024 - 2033 ($Billion)
Table 11. Europe Vaccines Market for Meningococcal Disease, by Country, 2024 - 2033 ($Billion)
Table 12. Europe Vaccines Market for Rotavirus, by Country, 2024 - 2033 ($Billion)
Table 13. Europe Vaccines Market for Varicella, by Country, 2024 - 2033 ($Billion)
Table 14. Europe Vaccines Market for Measles, Mumps, and Rubella, by Country, 2024 - 2033 ($Billion)
Table 15. Europe Vaccines Market for Diphtheria, Pertussis, and Tetanus (Dtp), by Country, 2024 - 2033 ($Billion)
Table 16. Europe Vaccines Market for Polio, by Country, 2024 - 2033 ($Billion)
Table 17. Europe Vaccines Market for Hepatitis, by Country, 2024 - 2033 ($Billion)
Table 18. Europe Vaccines Market for Other Indications, by Country, 2024 - 2033 ($Billion)
Table 19. Europe Vaccines Market, by End-user, 2024 - 2033 ($Billion)
Table 20. Europe Vaccines Market for Pediatric, by Country, 2024 - 2033 ($Billion)
Table 21. Europe Vaccines Market for Adults, by Country, 2024 - 2033 ($Billion)
Table 22. Europe Vaccines Market for Travelers, by Country, 2024 - 2033 ($Billion)
Table 23. Europe Vaccines Market, by Country, 2024 - 2033 ($Billion)
Table 24. Europe Vaccines Market, by Technology Type, 2024 - 2033 ($Billion)
Table 25. Europe Vaccines Market, by Indication, 2024 - 2033 ($Billion)
Table 26. Europe Vaccines Market, by End-user, 2024 - 2033 ($Billion)
Table 27. Germany Vaccines Market, by Technology Type, 2024 - 2033 ($Billion)
Table 28. Germany Vaccines Market, by Indication, 2024 - 2033 ($Billion)
Table 29. Germany Vaccines Market, by End-user, 2024 - 2033 ($Billion)
Table 30. France Vaccines Market, by Technology Type, 2024 - 2033 ($Billion)
Table 31. France Vaccines Market, by Indication, 2024 - 2033 ($Billion)
Table 32. France Vaccines Market, by End-user, 2024 - 2033 ($Billion)
Table 33. UK Vaccines Market, by Technology Type, 2024 - 2033 ($Billion)
Table 34. UK Vaccines Market, by Indication, 2024 - 2033 ($Billion)
Table 35. UK Vaccines Market, by End-user, 2024 - 2033 ($Billion)
Table 36. Italy Vaccines Market, by Technology Type, 2024 - 2033 ($Billion)
Table 37. Italy Vaccines Market, by Indication, 2024 - 2033 ($Billion)
Table 38. Italy Vaccines Market, by End-user, 2024 - 2033 ($Billion)
Table 39. Spain Vaccines Market, by Technology Type, 2024 - 2033 ($Billion)
Table 40. Spain Vaccines Market, by Indication, 2024 - 2033 ($Billion)
Table 41. Spain Vaccines Market, by End-user, 2024 - 2033 ($Billion)
Table 42. Rest of Europe Vaccines Market, by Technology Type, 2024 - 2033 ($Billion)
Table 43. Rest of Europe Vaccines Market, by Indication, 2024 - 2033 ($Billion)
Table 44. Rest of Europe Vaccines Market, by End-user, 2024 - 2033 ($Billion)
Table 45. Pfizer: Key Executives
Table 46. Pfizer: Company Snapshot
Table 47. Pfizer: Operating Segments
Table 48. Pfizer: Product Portfolio
Table 49. Pfizer: Key Strategic Moves and Developments
Table 50. Bavarian Nordic A/S: Key Executives
Table 51. Bavarian Nordic A/S: Company Snapshot
Table 52. Bavarian Nordic A/S: Operating Segments
Table 53. Bavarian Nordic A/S: Product Portfolio
Table 54. Bavarian Nordic A/S: Key Strategic Moves and Developments
Table 55. Valneva SE: Key Executives
Table 56. Valneva SE: Company Snapshot
Table 57. Valneva SE: Operating Segments
Table 58. Valneva SE: Product Portfolio
Table 59. Valneva SE: Key Strategic Moves and Developments
Table 60. Viatris Inc.: Key Executives
Table 61. Viatris Inc.: Company Snapshot
Table 62. Viatris Inc.: Operating Segments
Table 63. Viatris Inc.: Product Portfolio
Table 64. Viatris Inc.: Key Strategic Moves and Developments
Table 65. Astrazeneca: Key Executives
Table 66. Astrazeneca: Company Snapshot
Table 67. Astrazeneca: Operating Segments
Table 68. Astrazeneca: Product Portfolio
Table 69. Astrazeneca: Key Strategic Moves and Developments
Table 70. Emergex Vaccines: Key Executives
Table 71. Emergex Vaccines: Company Snapshot
Table 72. Emergex Vaccines: Operating Segments
Table 73. Emergex Vaccines: Product Portfolio
Table 74. Emergex Vaccines: Key Strategic Moves and Developments
Table 75. Sanofi: Key Executives
Table 76. Sanofi: Company Snapshot
Table 77. Sanofi: Operating Segments
Table 78. Sanofi: Product Portfolio
Table 79. Sanofi: Key Strategic Moves and Developments
Table 80. Prokarium: Key Executives
Table 81. Prokarium: Company Snapshot
Table 82. Prokarium: Operating Segments
Table 83. Prokarium: Product Portfolio
Table 84. Prokarium: Key Strategic Moves and Developments
Table 85. Merck and Co. Inc.: Key Executives
Table 86. Merck and Co. Inc.: Company Snapshot
Table 87. Merck and Co. Inc.: Operating Segments
Table 88. Merck and Co. Inc.: Product Portfolio
Table 89. Merck and Co. Inc.: Key Strategic Moves and Developments
Table 90. Gsk PLC.: Key Executives
Table 91. Gsk PLC.: Company Snapshot
Table 92. Gsk PLC.: Operating Segments
Table 93. Gsk PLC.: Product Portfolio
Table 94. Gsk PLC.: Key Strategic Moves and Developments
LIST OF FIGURES
Figure 1. Europe Vaccines Market,2024 - 2033
Figure 2. Segmentation of Europe Vaccines Market,2024 - 2033
Figure 3. Top Investment Pocket in Europe Vaccines Market,2024 - 2033
Figure 4. Moderate Bargaining Power of Buyers
Figure 5. Moderate Bargaining Power of Suppliers
Figure 6. Moderate Threat of New Entrants
Figure 7. Low Threat of Substitution
Figure 8. High Competitive Rivalry
Figure 9. Opportunities, Restraints and Drivers: Europe Vaccines Market
Figure 10. Europe Vaccines Market , by Technology Type,2024 - 2033 ($Billion)
Figure 11. Europe Vaccines Market for Inactivated Vaccines, by Country, 2024 - 2033 ($Billion)
Figure 12. Europe Vaccines Market for Toxoid Vaccines, by Country, 2024 - 2033 ($Billion)
Figure 13. Europe Vaccines Market for Recombinant and Conjugate Vaccines, by Country, 2024 - 2033 ($Billion)
Figure 14. Europe Vaccines Market for Live Attenuated Vaccines, by Country, 2024 - 2033 ($Billion)
Figure 15. Europe Vaccines Market for Others, by Country, 2024 - 2033 ($Billion)
Figure 16. Europe Vaccines Market , by Indication,2024 - 2033 ($Billion)
Figure 17. Europe Vaccines Market for Pneumococcal Disease, by Country, 2024 - 2033 ($Billion)
Figure 18. Europe Vaccines Market for Influenza, by Country, 2024 - 2033 ($Billion)
Figure 19. Europe Vaccines Market for Human Papilloma Virus, by Country, 2024 - 2033 ($Billion)
Figure 20. Europe Vaccines Market for Meningococcal Disease, by Country, 2024 - 2033 ($Billion)
Figure 21. Europe Vaccines Market for Rotavirus, by Country, 2024 - 2033 ($Billion)
Figure 22. Europe Vaccines Market for Varicella, by Country, 2024 - 2033 ($Billion)
Figure 23. Europe Vaccines Market for Measles, Mumps, and Rubella, by Country, 2024 - 2033 ($Billion)
Figure 24. Europe Vaccines Market for Diphtheria, Pertussis, and Tetanus (Dtp), by Country, 2024 - 2033 ($Billion)
Figure 25. Europe Vaccines Market for Polio, by Country, 2024 - 2033 ($Billion)
Figure 26. Europe Vaccines Market for Hepatitis, by Country, 2024 - 2033 ($Billion)
Figure 27. Europe Vaccines Market for Other Indications, by Country, 2024 - 2033 ($Billion)
Figure 28. Europe Vaccines Market , by End-user,2024 - 2033 ($Billion)
Figure 29. Europe Vaccines Market for Pediatric, by Country, 2024 - 2033 ($Billion)
Figure 30. Europe Vaccines Market for Adults, by Country, 2024 - 2033 ($Billion)
Figure 31. Europe Vaccines Market for Travelers, by Country, 2024 - 2033 ($Billion)
Figure 32. Top Winning Strategies, by Year, 2021-2023*
Figure 33. Top Winning Strategies, by Development, 2021-2023*
Figure 34. Top Winning Strategies, by Company, 2021-2023*
Figure 35. Product Mapping of Top 10 Players
Figure 36. Competitive Dashboard
Figure 37. Competitive Heatmap: Europe Vaccines Market
Figure 38. Top Player Positioning,2023
Figure 39. Pfizer: Net Sales, 2021-2023 ($Billion)
Figure 40. Pfizer: Revenue Share, by Segment, 2023 (%)
Figure 41. Pfizer: Revenue Share, by Region, 2023 (%)
Figure 42. Bavarian Nordic A/S: Net Sales, 2021-2023 ($Billion)
Figure 43. Bavarian Nordic A/S: Revenue Share, by Segment, 2023 (%)
Figure 44. Bavarian Nordic A/S: Revenue Share, by Region, 2023 (%)
Figure 45. Valneva SE: Net Sales, 2021-2023 ($Billion)
Figure 46. Valneva SE: Revenue Share, by Segment, 2023 (%)
Figure 47. Valneva SE: Revenue Share, by Region, 2023 (%)
Figure 48. Viatris Inc.: Net Sales, 2021-2023 ($Billion)
Figure 49. Viatris Inc.: Revenue Share, by Segment, 2023 (%)
Figure 50. Viatris Inc.: Revenue Share, by Region, 2023 (%)
Figure 51. Astrazeneca: Net Sales, 2021-2023 ($Billion)
Figure 52. Astrazeneca: Revenue Share, by Segment, 2023 (%)
Figure 53. Astrazeneca: Revenue Share, by Region, 2023 (%)
Figure 54. Emergex Vaccines: Net Sales, 2021-2023 ($Billion)
Figure 55. Emergex Vaccines: Revenue Share, by Segment, 2023 (%)
Figure 56. Emergex Vaccines: Revenue Share, by Region, 2023 (%)
Figure 57. Sanofi: Net Sales, 2021-2023 ($Billion)
Figure 58. Sanofi: Revenue Share, by Segment, 2023 (%)
Figure 59. Sanofi: Revenue Share, by Region, 2023 (%)
Figure 60. Prokarium: Net Sales, 2021-2023 ($Billion)
Figure 61. Prokarium: Revenue Share, by Segment, 2023 (%)
Figure 62. Prokarium: Revenue Share, by Region, 2023 (%)
Figure 63. Merck and Co. Inc.: Net Sales, 2021-2023 ($Billion)
Figure 64. Merck and Co. Inc.: Revenue Share, by Segment, 2023 (%)
Figure 65. Merck and Co. Inc.: Revenue Share, by Region, 2023 (%)
Figure 66. Gsk PLC.: Net Sales, 2021-2023 ($Billion)
Figure 67. Gsk PLC.: Revenue Share, by Segment, 2023 (%)
Figure 68. Gsk PLC.: Revenue Share, by Region, 2023 (%)
